Vexed surgeons, perplexed patients, and breast cancers which may not be cancer.

A. S. Ketcham, Frederick L Moffat

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

In situ cancer of the breast is being diagnosed with increasing frequency due to the widespread use of mammography and heightened awareness of these lesions among pathologists. Treatment of these preinvasive cancers is controversial in light of recent data supporting breast-conserving therapy for small invasive cancers. Therapy for in situ breast cancer is discussed with attention to known risk factors for recurrence and breast cancer-related mortality. The controversies surrounding treatment of ductal and lobular carcinoma in situ compel the conscientious oncologist to seek fully informed consent and to respect the individual patient's feelings about cosmesis and breast cancer risk. Hopefully, prospective randomized studies such as the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-17 trial will relieve the oncology community of much of its confusion about the natural history and optimal therapy for these diseases.

Original languageEnglish
Pages (from-to)387-393
Number of pages7
JournalCancer
Volume65
Issue number3
StatePublished - Feb 1 1990

Fingerprint

Breast Neoplasms
Neoplasms
Breast
Therapeutics
Carcinoma, Intraductal, Noninfiltrating
Mammography
Natural History
Informed Consent
Emotions
Surgeons
Prospective Studies
Recurrence
Mortality

ASJC Scopus subject areas

  • Cancer Research

Cite this

Vexed surgeons, perplexed patients, and breast cancers which may not be cancer. / Ketcham, A. S.; Moffat, Frederick L.

In: Cancer, Vol. 65, No. 3, 01.02.1990, p. 387-393.

Research output: Contribution to journalArticle

@article{178b0017950940bc91239fe6c3f9138d,
title = "Vexed surgeons, perplexed patients, and breast cancers which may not be cancer.",
abstract = "In situ cancer of the breast is being diagnosed with increasing frequency due to the widespread use of mammography and heightened awareness of these lesions among pathologists. Treatment of these preinvasive cancers is controversial in light of recent data supporting breast-conserving therapy for small invasive cancers. Therapy for in situ breast cancer is discussed with attention to known risk factors for recurrence and breast cancer-related mortality. The controversies surrounding treatment of ductal and lobular carcinoma in situ compel the conscientious oncologist to seek fully informed consent and to respect the individual patient's feelings about cosmesis and breast cancer risk. Hopefully, prospective randomized studies such as the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-17 trial will relieve the oncology community of much of its confusion about the natural history and optimal therapy for these diseases.",
author = "Ketcham, {A. S.} and Moffat, {Frederick L}",
year = "1990",
month = "2",
day = "1",
language = "English",
volume = "65",
pages = "387--393",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Vexed surgeons, perplexed patients, and breast cancers which may not be cancer.

AU - Ketcham, A. S.

AU - Moffat, Frederick L

PY - 1990/2/1

Y1 - 1990/2/1

N2 - In situ cancer of the breast is being diagnosed with increasing frequency due to the widespread use of mammography and heightened awareness of these lesions among pathologists. Treatment of these preinvasive cancers is controversial in light of recent data supporting breast-conserving therapy for small invasive cancers. Therapy for in situ breast cancer is discussed with attention to known risk factors for recurrence and breast cancer-related mortality. The controversies surrounding treatment of ductal and lobular carcinoma in situ compel the conscientious oncologist to seek fully informed consent and to respect the individual patient's feelings about cosmesis and breast cancer risk. Hopefully, prospective randomized studies such as the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-17 trial will relieve the oncology community of much of its confusion about the natural history and optimal therapy for these diseases.

AB - In situ cancer of the breast is being diagnosed with increasing frequency due to the widespread use of mammography and heightened awareness of these lesions among pathologists. Treatment of these preinvasive cancers is controversial in light of recent data supporting breast-conserving therapy for small invasive cancers. Therapy for in situ breast cancer is discussed with attention to known risk factors for recurrence and breast cancer-related mortality. The controversies surrounding treatment of ductal and lobular carcinoma in situ compel the conscientious oncologist to seek fully informed consent and to respect the individual patient's feelings about cosmesis and breast cancer risk. Hopefully, prospective randomized studies such as the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-17 trial will relieve the oncology community of much of its confusion about the natural history and optimal therapy for these diseases.

UR - http://www.scopus.com/inward/record.url?scp=0025377172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025377172&partnerID=8YFLogxK

M3 - Article

C2 - 2404554

AN - SCOPUS:0025377172

VL - 65

SP - 387

EP - 393

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -